DRREDDY:NSE
ドクター・レッディーズ・ラボラトリーズ
₹1,204.80
arrow_downward
-0.12%(-1.40) 1 日
10月5日, 15:30:00 GMT+5:30 · INR
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoDRREDDY の上位の分析情報を生成しています...
始値
₹1,198.00
高値
₹1,206.60
安値
₹1,189.00
時価総額
1.00兆
平均出来高
172.24万
取引量
307.60万
配当
0.66%
四半期配当
₹2.00
配当落ち日
2026/07/10
株価収益率
31.16
52 週高値
₹1,414.90
52 週安値
₹1,101.00
EPS
₹38.67
発行済株式数
1.66億
従業員数
3万
始値
₹1,198.00
高値
₹1,206.60
安値
₹1,189.00
時価総額
1.00兆
平均出来高
172.24万
取引量
307.60万
配当
0.66%
四半期配当
₹2.00
配当落ち日
2026/07/10
株価収益率
31.16
52 週高値
₹1,414.90
52 週安値
₹1,101.00
EPS
₹38.67
発行済株式数
1.66億
従業員数
3万
ニュース記事
情報源: ウェブソース、ニュース パートナー
プロフィール
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
ドクター・レッディーズ・ラボラトリーズ について